Device Clinical Research Trials – John Paul Runyon as Sub-Investigator


Sub-Investigator
Global Therapeutics
Magellan coronary dilation catheter.

Co-Investigator
NIR VASCULAR ADVANCED NORTH AMERICAN TRIAL (NIRVANA TRIAL) (NIR STENT) .

Sub-Investigator
EXTRA: Evaluation of the XT Stent for Restenosis in Native Arteries.

Co-Investigator
Randomized trial of localized radiation therapy to inhibit restenosis after stenting.

Sub-Investigator
ACS Multi-Link Duet Coronary Stent system in treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
Angiorad Radiation for RESTenosis Unstented Native Vessels (ARREST).

Sub-Investigator
Palmaz-Schatz Mini Crown balloon expandable stent mounted on the Cordis Dynasty OTW delivery system for pts undergoing elective MiniCrown stent placement vs. angioplasty in small coronary arteries (MICA).

Sub-Investigator
Angiorad radiation therapy for in-stent restenosis intra coronaries (ARTISTIC).

Sub-Investigator
Non-randomized, prospective, multicenter, consecutive registry of native coronary artery and arterial bypass graft conduits with the AVE GFX 2.5 stent for acute or threatened closure indication.

Sub-Investigator
Guidant intravascular radiotherapy system in the treatment of in-stent restenosis.

Sub-Investigator
DISTINCT Trial: Biocompatibles Stent.

Sub-Investigator
GAMMA II: Multicenter trial of localized radiation therapy to inhibition restenosis after stenting.

Sub-Investigator
ACS Multi Link ULTRA coronary stent system in pts with SVG and native coronary artery lesions.

Sub-Investigator
PREDICT Trial for S670 coronary stent system: Predilitation vs. direct stenting in coronary treatment.

Sub-Investigator
GAMMA IV: Continued access trial of localized radiation therapy to inhibit restenosis after stenting.

Sub-Investigator
SLIDE Registry: Select lesion indication for direct stenting: Registry to evaluate the ACS MULTI-LINK Tristar stent system in treatment of patients with de novo and restenotic native coronary artery lesions using a no pre-dilatation implantation strategy.

Sub-Investigator
High Scaffolding SVG Registry (Medtronic AVE).

Sub-Investigator
Antrin injection & far red light activation in pts. with CAD undergoing PCI with stent placement (Antrin/PTCA).

Sub-Investigator
X-TRACT: X-Sizer for Treatment of Thrombus & Atherosclerosis in Coronary Interventions Trial.

Sub-Investigator
CONSERVE: Comparison of new stents for equivalency of reduction in vascular events.

Sub-Investigator
A non-randomized evaluation of the multi-link rx tetra coronary stent system in the tx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
Biocompatibles BiodivYsioTM stent non-randomized control trial (DISTINCT Stent Sizes Registry).

Sub-Investigator
QUICKSEAL delivery system for achieving hemostasis of the arterial access site as compared to manual compression.

Sub-Investigator
GAMMA V: A multicenter trial of localized radiation therapy to inhibit restenosis.

Sub-Investigator
TENAX XR Registry (coronary stent study).

Sub-Investigator
SWING: Sound Wave Inhibition of Neointimal Growth.

Sub-Investigator
ARTISTIC II: AngioRad radiation therapy for in-stent restenosis intracoronaries.

Sub-Investigator
TRAP Vascular Filtration System Trial.

Sub-Investigator
A non-randomized evaluation of the MULTI-LINK RX PENTA coronary stent system in the rx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
SIRIUS Study: A multicenter, randomized, double blind study of the Sirolimus-Coated Bx VELOCITY balloon-expandable stent in the tx. of pts. with de novo coronary artery lesions.

Sub-Investigator
BRITE II Trial: The Beta Radiation to Reduce In-Stent Restenosis II Trial.

Sub-Investigator
VICTORY: Elective & acute stenting of coronary arteries on Express System.

Sub-Investigator
MULTI-LINK VISION Registry: A non-randomized evaluation of the MULTI-LINK VISION Coronary Stent System in the Tx. of Pts. with de novo Native Coronary Artery Lesions.

Sub-Investigator
JOSTENT SVG BARRICADE Trial: The Barrier Approach to Restenosis: Restrict Intima & Curtail Adverse Events).

Sub-Investigator
Repeat intracoronary radiation for patients who failed radiation therapy: a compassionate use protocol.

Sub-Investigator
DELIVER: Prospective, Randomized…. evaluation of the Rx Achieve drug-coated coronary stent system in the tx. of pts. with de novo native coronary artery lesions.

Sub-Investigator
Filter Wire During Transluminal Intervention of Saphenous Vein Grafts (FIRE).

Sub-Investigator
TAXUS IV: A prospective, randomized…TAXUS Paclitaxel-eluting coronary stent in de novo coronary lesions & in-stent restenosis.

Sub-Investigator
Medtronic AVE S8 Coronary Stent System in denovo and restenotic lesions

Sub-Investigator
NIRFLEX stent study.

Sub-Investigator
ULTIMA: Multicenter, prospective study of the Sirolimus-eluting BX velocity balloon-expandable stent in the treatment of patients with unprotected left main coronary artery lesions.

Sub-Investigator
PREFER Trial: Prospective study to evaluate the safety and efficacy of two doses of ABT-578 coated BiodivYsio Stent for the Reduction of Restenosis.

Sub-Investigator
JOSTENT registry: for coronary artery perforations, coronary artery aneurysms and pseudoaneurysms and arteriovenous fistulas.

Sub-Investigator
Clinical evaluation of the Medtronic AVE Interceptor embolic protection device during PI on SVGs..

Sub-Investigator
TAXUS V: A randomized….trial to assess TAXUS Paclitaxel-eluting coronary stents, slow release formulation in the treatment of high risk de novo coronary lesions.

Principal Investigator
Medtronic AVE Micro-Drive Registry.

Sub-Investigator
The SLK-ViewTM Side-Access Coronary Stent Non-Randomized Pivotal Study.

Sub-Investigator
PROXIMAL protecting during saphenous vein graft intervention using the Proxis embolic protection system: a randomized, prospective multicenter, clinical trial.

Sub-Investigator
TAXUS V ISR: A prospective, randomized trial evaluating the slow-release formulation TAXUS paclitaxel-eluting coronary stent in the treatment of in-stent restenosis.

Sub-Investigator
Feasibility study of inducing mild hypothermia in acute MI using non-invasive cooling with Medivance® Artic SunTM system.

Sub-Investigator
SIRIUS: 2.25 mm: A multicenter, non-randomized study of the 2.25 mm Sirolimus-eluting BX Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
SIRIUS: 4.0 mm: A multicenter, non-randomized study of the 4.0 mm Sirolimus-eluting BX Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
ENDEAVOR III: A randomized controlled trial of the Medtronic Endeavor Drug (ABT-578) Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in de novo native coronary artery lesions.

Sub-Investigator
RESILIENT Trial: A Randomized study comparing the Edwards Self-Expanding LifeStent vs. angioplasty alone in lesions involving the SFA & proximal popliteal artery.

Sub-Investigator
A multicenter, non-randomized study of the CypherTM NxT Sirolimus-eluting coronary stent on the BX SonicTM Over-The-Wire (OTW) Stent Delivery System (SDS) for the treatment of de novo native coronary artery lesions.

Sub-Investigator
Future IV Clinical Trial: A Clinical evaluation of the CHAMPIONTM Everolimus Eluting Coronary Stent (EECS) System in the treatment of patients with de novo native coronary artery lesions.

Sub-Investigator
ZoMaxx II Trial: A randomized controlled trial to evaluate the safety and efficacy of the ZoMaxxTM Drug Eluting Coronary Stent System in de novo coronary arterial lesions.

Sub-Investigator
SPIRIT III: A clinical evaluation of the XIENCE V Everolimus Eluting Coronary Stent (EECS) System in the treatment of subjects with de novo native coronary artery lesions.

Sub-Investigator
COSTAR Trial: CObalt chromium STent with Antiproliferative for Restenosis.

Sub-Investigator
ENDEAVOR IV: A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System versus the TaxusTm Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Sub-Investigator
SPIRIT IV: XIENCE V Everolimus Eluting Coronary Stent System in the Tx. of Sub. with de novo Native Coronary Artery Lesion.

Sub-Investigator
TAXUS PERSEUS: A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the treatment of de novo coronary artery lesions in small vessels.

Sub-Investigator
TAXUS PERSEUS: WORKHORSE: A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the treatment of de novo coronary artery lesions.

Sub-Investigator
RETRIEVE Study: Evaluating the use of the FiberNet Embolic Protection System in saphenous vein grafts.

Sub-Investigator
A prospective, single blind, randomized, multi-center, study comparing the CYPHER® ELITETM and the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems.

Sub-Investigator
CORAL: Cardiovascular Outcomes in Renal Atherosclerotic Lesions.

Sub-Investigator
PROTECT II: A prospective, multi-center, randomized controlled trial of the IMPELLA® RECOVER® LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in patients undergoing non emergent high risk PCI.

Sub-Investigator
A clinical evaluation of the ABT Everolimus Eluting Coronary Stent System: SPIRIT Small Vessel/Long Lesion Clinical Trial

Co-Investigator
XIENCETM V Everolimus Eluting Coronary Stent System (EECSS) USA post-approval study.

Sub-Investigator
SPIRIT Small Vessel Registry (SPIRIT SV) Clinical Trial: A clinical evaluation of the 2.25mm XIENCE V Everolimus eluting coronary stent system.

Sub-Investigator
RESOLUTE: A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm.

Sub-Investigator
SPIRIT Small Vessel Registry (SPIRIT SV) Clinical Trial: A clinical evaluation of the 2.25mm XIENCE V Everolimus Eluting Coronary Stent System.

Sub-Investigator
RESOLUTE: A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm.

Sub-Investigator
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS ElementTM) for the Treatment of up to two De Novo Coronary Artery Lesions..

Sub-Investigator
SPIRIT PRIME Clinical Trial: A clinical evaluation of the XIENCE PRIMETM and XIENCE PRIMETM LL Everolimus Eluting Coronary Stent System.

Sub-Investigator
CYPRESS: P09-6301: A prospective, randomized, multi-center, double-blind trial to assess the effectiveness and safety of different durations of Dual Anti-Platelet Therapy (DAPT) in subjects undergoing percutaneous coronary intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent).

Sub-Investigator
ROSS Clinical Study: A Clinical evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions.

Sub-Investigator
OMEGA: A prospective, multicenter single-arm trial to assess the OMEGATM coronary stent system for the treatment of a single de novo coronary artery lesion.